ECCMID 25th (2015)

Drupal spam blocked by CleanTalk.
Title Content type
An open-label phase 3 study of Isavuconazole (VITAL): focus on patients with mixed fungal infections (click for details)
Drug interaction profiles of Isavuconazole, voriconazole and posaconazole with immunosuppressants metabolized by CYP4503A4 (CYP3A4) – (click for details)
A comparison of the safety profiles of Isavuconazole vs voriconazole in the phase 3 SECURE study in patients with invasive mould infections – (click for details)
Successful treatment of contaminated epidural steroid associated fungal meningitis with Isavuconazole (click for details)
Safety and outcomes in invasive aspergillosis patients with renal vs. no renal impairment treated with Isavuconazole: experience from the SECURE (randomized) and VITAL trials (click for details)
Safety and outcomes in obese patients with invasive fungal disease treated with Isavuconazole in the phase 3 randomised double-blind SECURE trial – (click for details)
Outcome of invasive aspergillosis after allogeneic haematopoietic stemcell transplantation in patientswith invasive aspergillosis before transplantation (click for details)
Comparative analysis of patients with chronic pulmonary aspergillosis and invasive pulmonary aspergillosis: a ten-year retrospective study (click for details)
Performance of Aspergillus PCR and multifungal DNA microarray for diagnosis of invasive fungal infections in clinical samples from ICU patients with suspected fungal infections (click for details)
Impact of dose fractionation on the in vivo efficacy of isavuconazole in a murine model of Aspergillus fumigatus infection (click for details)


Subscribe to ECCMID 25th (2015)